TWO:6535

Lumosa Therapeutics Co., Ltd. · TWO · Healthcare · TWD · FY for 2025

Figures on this page computed 2026-11-08 12:50 UTC

Last close

n/aTWD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
TWD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-967.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
-996.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
TWD
- computed

Price is the furthest below its sector's middle: 0.07 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.75x

1.41x

1.39x

0.67x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.75x
Its own average over 10 years, 47.8M.
Profit1.41x
Its own average over 10 years, -246.5M.
Free cash flow1.39x
Its own average over 10 years, -256.7M.
Debt0.67x
Its own average over 7 years, 10.4M.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at 1.41 times.

Sales is 0.75 times its own 10-year average; Profit is 1.41 times its own 10-year average; Free cash flow is 1.39 times its own 10-year average; Debt is 0.67 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average0.75
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Profit against its own 10-year average1.41
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Free cash flow against its own 10-year average1.39
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Debt against its own 7-year average0.67
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
TWD